Biotechnology

Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia

TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...

2022-02-17 21:00 1382

PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs

NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory A...

2022-02-16 20:00 1381

Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team

PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...

2022-02-15 21:00 1446

HPG: New Breakthrough in Virus Inactivation with Green Tea Catechin (EGCg)

TOKYO, Feb. 15, 2022 /PRNewswire/ -- HPG Co., Ltd. (Chuo-ku, Tokyo) has successfully developed a water-soluble formulation technology of highly concentrated catechin EGCg (Epigallocatechin gallate) with excellent storage stability and initiated procedures for a patent application for the technolo...

2022-02-15 16:00 1267

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient inChina in its multi-regi...

2022-02-11 20:40 3978

WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories

SHANGHAI, Feb. 10, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service and scored as a 2022 CMO Leadership Award Champi...

2022-02-11 10:00 1578

Ucello Therapeutics Completes US$25 Million Series A Financing

SAN DIEGO, Calif. and CHENGDU, China, Feb. 10, 2022 /PRNewswire/ -- Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of aUS$25 million Series A financing. The funding round was led by Matrix Partners China, alon...

2022-02-11 02:16 1754

AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)

HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody (research and development code: AK115) injection developed in-house by the Company, has obtained approval from the Centre fo...

2022-02-10 17:00 1688

Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients

* Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health * Data shows that 51% of participants achieved sustained unresponsiveness (clinical remission) to peanut after 18 months of treatment * Prota Therapeutics announces new round of capital raising for fur...

2022-02-09 20:00 1247

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...

2022-02-09 17:12 1493

Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics

* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...

2022-02-08 06:00 1589

IonOpticks enters OEM partnership with Bruker that sets a new standard for mass spectrometry-based research

MELBOURNE, Australia, Feb. 7, 2022 /PRNewswire/ -- Premium manufacturer of chromatography for proteomics applications, IonOpticks, has entered an OEM partnership with the Bruker Corporation (Nasdaq: BRKR), allowing Bruker to expand their portfolio of 4D-Proteomics solutions with the release of th...

2022-02-08 00:01 1856

Samsung Biologics receives 2022 CMO Leadership Award in all six categories

INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science ...

2022-02-07 20:00 1742

Laekna Launched the new domain name www.laekna.com

SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct or indirect subsidiaries, including Laekna Therapeutics Shanghai Co., Ltd.), an emerging innovative biotech based inChina's "Zhangjiang Pharma Valley" andNew Jersey in the U.S. and focused on devel...

2022-02-07 12:47 1362

Genesis MedTech Acquires JC Medical, Creates New Structural Heart Franchise

SINGAPORE, Feb. 4, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a  structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment ...

2022-02-05 08:00 3832

Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report

SYDNEY, Feb. 4, 2022 /PRNewswire/ -- Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10 CRO in the2021 CenterWatch Global Site Relationship Benchmark Survey. Report available here

2022-02-04 19:47 3351

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...

2022-02-04 06:54 2295

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it had reached an agreement with TheScripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps...

2022-02-03 22:00 1571

New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good

TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...

2022-02-01 21:00 1897

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...

2022-01-31 19:00 1528
1 ... 64656667686970 ... 110